Alembic Pharmaceuticals Limited recently announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bimatoprost Ophthalmic Solution, 0.03%.
The approved product is therapeutically equivalent to the reference listed drug product Patanol ophthalmic solution, 0.1 per cent, of Novartis Pharmaceuticals Corporation